Document is current
Any future updates will be listed below
-
Authors
Hyldegaard, Ole https://orcid.org/0000-0002-1147-379X
Nekludov, Michael https://orcid.org/0000-0001-9916-7086
Arnell, Per https://orcid.org/0000-0003-0140-4915
Nedrebø, Torbjørn https://orcid.org/0000-0002-8911-5837
Karlsson, Ylva
Madsen, Martin Bruun https://orcid.org/0000-0001-5832-2262
Skrede, Steinar https://orcid.org/0000-0003-1615-4453
Dos Santos, Vitor Martins https://orcid.org/0000-0002-2352-9017
Svensson, Mattias https://orcid.org/0000-0003-1695-7934
Perner, Anders https://orcid.org/0000-0002-4668-0123
Vinkel, Julie https://orcid.org/0000-0002-1251-352X
Kjellberg, Anders https://orcid.org/0000-0002-4819-1024
Rosén, Anders https://orcid.org/0000-0001-6739-6730
Douglas, Johan https://orcid.org/0000-0003-1018-9719
Bruun, Trond https://orcid.org/0000-0002-7441-8413
Hardt, Christopher https://orcid.org/0000-0002-8093-4131
Norrby-Teglund, Anna https://orcid.org/0000-0001-9372-1795
Hedetoft, Morten https://orcid.org/0000-0002-2606-8041
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01790698 at ClinicalTrials.govDocuments that mention this clinical trial
Biomarkers of necrotising soft tissue infections: aspects of the innate immune response and effects of hyperbaric oxygenation—the protocol of the prospective cohort BIONEC study
https://doi.org/10.1136/bmjopen-2014-006995
How biomarkers reflect the prognosis and treatment of necrotising soft tissue infections and the effects of hyperbaric oxygen therapy: the protocol of the prospective cohort PROTREAT study conducted at a tertiary hospital in Copenhagen, Denmark
https://doi.org/10.1136/bmjopen-2017-017805
Use of Hyperbaric Oxygen in Patients with Necrotizing Soft Tissue Infections: A Scandinavian Multicenter, Prospective, Observational Cohort
https://doi.org/10.1007/s40121-025-01184-5
Hyperbaric oxygen treatment impacts oxidative stress markers in patients with necrotizing soft-tissue infection
https://doi.org/10.1136/jim-2021-001837
Key pathways and genes that are altered during treatment with hyperbaric oxygen in patients with sepsis due to necrotizing soft tissue infection (HBOmic study)
https://doi.org/10.1186/s40001-023-01466-z
-
Funding
Funding for this research was provided by:
Seventh Framework Programme (305340)
Innovationsfonden (8113-00009B, 8114-00005B)
Horizon 2020 Framework Programme (2018-151)
Ellabfonden Danmark
- License Information
-
More Information
Article History
Received: 10 April 2025
Accepted: 10 June 2025
First Online: 4 July 2025
Declarations
:
: No conflicts of interest, financial or otherwise, are declared by the authors Ole Hyldegaard, Michael Nekludov, Per Arnell, Torbjørn Nedrebø, Ylva Karlsson, Martin Bruun Madsen, Steinar Skrede, Vitor Martins Dos Santos, Mattias Svensson, Anders Perner, Julie Vinkel, Anders Kjellberg, Anders Rosén, Johan Douglas, Trond Bruun, Christopher Hardt, Anna Norrby-Teglund, Morten Hedetoft to this report.
: All participating clinical study centers were granted study approvals from their national- or regional ethics committees as well as approvals from their respective data protection agencies []. Written informed consent, including the consent to publish the study results, was obtained from all patients or their legal surrogate as soon as possible and during the acute phase of the treatment period, according to national legislation. Subsequently, for patients where immediate consent was not possible, we obtained consent from the patient when possible []. The study was conducted in accordance with the World Medical Association’s Code of Ethics (Declaration of Helsinki 1964 and its later amendments). The INFECT study was approved at all involved study centers under the governance of the Regionala etikprövningsnämnden i Göteborg – Västra Götalandsregionen Dnr 930–12, Den Nationale Videnskabs Etiske Kommitte (DNVK – sag nr. 1211709, dok.nr. 1151739) and the REK – Regionale Komiteer for medisinsk og helsefaglig forskningsetikk, ref. 2012/2227/REK vest.
